Unlocking a New Path to Treat Hyperphagia in PWS: A Conversation with Aardvark Therapeutics
Hyperphagia, the relentless hunger that those living with Prader-Willi syndrome (PWS) experience, remains one of the most challenging and life-altering symptoms for individuals and families. But a promising investigational drug called ARD-101 is offering hope. In our April 29th episode of PWS United, Aardvark Therapeutics’ Dr. Tien Lee, M.D., CEO and Founder, and Dr. Manasi...
Free Live Webinar: Understanding VYKAT XR – The First FDA-Approved Treatment for Hyperphagia in PWS
Date: Wednesday, April 16, 2025Time: 9:15 AM PT | 12:15 PM ETLocation: Virtual via ZOOM The Prader-Willi syndrome (PWS) community has reached a historic milestone – VYKAT XR (formerly known as DCCR in clinical trials) is now FDA-approved as the first-ever treatment for hyperphagia in PWS. To help families, caregivers, and healthcare providers understand what...
PWS Breaking News! FDA Approves First-Ever Treatment for Hyperphagia in PWS
We are thrilled to share with you this BREAKING NEWS for the PWS Community! The U.S. Food and Drug Administration (FDA) has officially approved VYKAT™ XR (diazoxide choline extended-release tablets, formerly referred to as DCCR) as the first-ever treatment for hyperphagia in Prader-Willi syndrome. This is a monumental victory for individuals with PWS, our families, and the entire rare disease...
Celebrating 50 Years of Hope: Ushering in PWSA | USA’s Anniversary Year
As the calendar turns to 2025, we at Prader-Willi Syndrome Association | USA (PWSA | USA) are filled with gratitude and anticipation. This year marks a monumental milestone: 50 years of supporting individuals with Prader-Willi syndrome (PWS) and their families through advocacy, education, research opportunities, and compassion. Our story began in 1975, when Gene and...